Arkolith/Insider Trading/CHRO/Form 4

Davis Todd C

DirectorChromocell Therapeutics Corp (CHRO) · full profile →Form 4 · filed Feb 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 21, 2024Option exercise(M)29K$4.80$140K29K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 21, 2024Conversion(C)0——0

Transaction Codes

M
Option exercise / conversion
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001753926-24-000374) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML